Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

QuidelOrtho Q3 2026 Results: Net Loss of $53.8M, Loss Narrows

QuidelOrtho reported a net loss of $53.8 million for the third quarter of 2026, a significant improvement from the $733.0 million loss in the prior year which was driven by a large goodwill impairment. Total revenues decreased to $618.9 million from $699.9 million year-over-year, while the company's accumulated deficit grew to $1,234.5 million.

Watch the QuidelOrtho Corp earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue618.9699.9
Profit before tax-62.9-756.9
Net income-53.8-733.0
EPS (diluted, $ a share)$-0.78$-10.78

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-11.6%
Operating margin-1.2%
Source

10-Q filed with the SEC, NASDAQ: QDEL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

QuidelOrtho Corp: key numbers

Share price
$10.21Close, Nov 16
Market cap
$701M
Shares outstanding
68.61MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from QuidelOrtho Corp

All →
4:10 PM ET 8-K
Financial Results

QuidelOrtho Financial Results

QuidelOrtho reported Q3 2026 revenue of $619 million, a 12% decrease year-over-year primarily due to lower sales in China and a softer respiratory season. The company also announced a major cost transformation and restructuring program expected to deliver over $80 million in annual savings by 2027, involving a shift to two focused business units: Core Diagnostics and Point of Care Diagnostics.

Term
Q3 2026

“The underlying performance of our Labs and Immunohematology businesses remained solid in the third quarter, supported by the strength and durability of our customer relationships and our large global installed base. While China and a softer respiratory season continue to pressure our results, we are taking decisive action to strengthen the Company through a new cost transformation and enterprise restructuring program.”

Brian J. Blaser, President and Chief Executive Officer
4:41 PM ET 8-K
Loan & Debt

QuidelOrtho $3.4B Debt Financing with Bank of America, N.A.

QuidelOrtho Corporation entered into an amendment to its existing credit agreement to reset financial covenant levels through September 30, 2029, providing a 'Covenant Relief Period' with adjusted leverage and interest coverage ratios. The underlying $3.4 billion financing package includes a $1.15 billion Term Loan A, a $100 million delayed draw facility, a $1.45 billion Term Loan B, and a $700 million revolving credit facility.

Value
$3.4B
Counterparty
Bank of America, N.A.
Term
through Sep 2029

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.